AI Summary
We reviewed 39 live results for interleukin inhibitor and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Interleukin Inhibitor and Immunosuppressant.
Comparison Table
Recommended
Skyrizi (Risankizumab)
Source: Skyrizi
Description
An interleukin inhibitor (IL-23) used for the treatment of active ulcerative colitis and moderate to severe plaque psoriasis. This biologic therapy targets specific immune pathways to reduce inflammation and promote healing.
Best for
plaque psoriasis treatment, active ulcerative colitis relief and IL-23 inhibitor preference
View Details
Rating
Cosentyx
Source: Novartis Malaysia
Description
Cosentyx (Secukinumab) is an interleukin inhibitor prescribed for plaque psoriasis and psoriatic arthritis. It is supplied as a 150 mg/mL solution for injection in a pre-filled pen or syringe.
Best for
plaque psoriasis, psoriatic arthritis and interleukin inhibition
View Details
Rating
Cosentyx 150mg/ml
Source: Novartis Corporation (Malaysia) Sdn. Bhd.
Description
Secukinumab solution for injection available in a pre-filled pen or pre-filled syringe. This interleukin-17A (IL-17A) inhibitor is indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in adults who are candidates for systemic therapy or phototherapy.
Best for
plaque psoriasis patients, psoriatic arthritis management, ankylosing spondylitis treatment and self-injection at home
View Details
Rating
| Compare | Skyrizi (Risankizumab) | Cosentyx | Cosentyx 150mg/ml |
|---|---|---|---|
| Source | Skyrizi | Novartis Malaysia | Novartis Corporation (Malaysia) Sdn. Bhd. |
| Description | An interleukin inhibitor (IL-23) used for the treatment of active ulcerative colitis and moderate to severe plaque psoriasis. This biologic therapy targets specific immune pathways to reduce inflammation and promote healing. | Cosentyx (Secukinumab) is an interleukin inhibitor prescribed for plaque psoriasis and psoriatic arthritis. It is supplied as a 150 mg/mL solution for injection in a pre-filled pen or syringe. | Secukinumab solution for injection available in a pre-filled pen or pre-filled syringe. This interleukin-17A (IL-17A) inhibitor is indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in adults who are candidates for systemic therapy or phototherapy. |
| Best for | plaque psoriasis treatment, active ulcerative colitis relief and IL-23 inhibitor preference | plaque psoriasis, psoriatic arthritis and interleukin inhibition | plaque psoriasis patients, psoriatic arthritis management, ankylosing spondylitis treatment and self-injection at home |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Skyrizi (Risankizumab) from Skyrizi."
I picked this because A newly approved biologic in Singapore (2025) providing advanced relief for chronic psoriasis and ulcerative colitis.
Share this search
Related Finds